Male breast cancer is almost always oestrogen receptor positive, and is traditionally treated in line with guidelines for treating hormone-sensitive breast cancers in postmenopausal women. Ian Fentiman questions the rationale for this approach, pointing to [more]
The impact chemotherapy can have on the ability to think clearly is well recognised. Less is known, however, about the cognitive effect of endocrine therapies, which in the adjuvant breast cancer setting are being prescribed [more]
The association of a treatment-related adverse effect with treatment success has been reported in various clinical situations. The development of vasomotor or joint symptoms is an indication of therapeutic benefit in women receiving endocrine treatment [more]